Target
Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4)
13 abstracts
Abstract
Impact of concurrent antibiotics on survival with immunotherapy in metastatic colorectal and pancreatic cancer.Org: BC Cancer-Vancouver Centre, Canadian Cancer Trials Group, Queen's University Belfast, Princess Margaret Cancer Centre and University of Toronto, Toronto, ON, Canada, Princess Margaret Cancer Centre,
Abstract
Nivolumab (NIVO) + chemotherapy (chemo) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): 4-year follow-up of CheckMate 649.Org: Johannes-Gutenberg University Clinic, Mainz, Germany, Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Beijing, China, Clinica San Carlos de Apoquindo, Pontificia Universidad Católica, Santiago, Chile, Fundacion Arturo López Pérez, Providencia, Chile, Klinika Onkologii i Radioterapii, Narodowy Instytut Onkologii, Warszawa, Poland,
Abstract
Neoadjuvant immune checkpoint inhibitors for patients with resectable stage III/IV melanoma: A nationwide real-life study in France (NEOMEL).Org: University Hospital Jean Minjoz, Université de Franche-Comté, Inserm RIGHT, Besançon, CHU de Bordeaux,
Abstract
Efficacy and safety of first-line TKI plus ICI therapy in metastatic non-clear cell renal cell carcinoma: A real-world multiple-centre study.Org: Department of Urology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Department of Urology, Xiangya Hospital Central South Universiity, Department of Urology, Sun Yat-sen University Cancer Center; State Key Laboratory of Oncology in South China; Collaborative Innovation Center of Cancer Medicine, Department of Urology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Department of Urology, Disorders of Prostate Cancer Multidisciplinary Team, National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University,
Abstract
The impact of renin-angiotensin-aldosterone system inhibitors on immune checkpoint inhibitor-associated adverse cardiovascular events.Org: National Taiwan University Hospital Yunlin Branch, Mount Auburn Hospital, Harvard Medical School, Cambridge University Hospitals NHS Foundation Trust, Taipei TzuChi Hospital,
Abstract
Response to immune checkpoint inhibitor (ICI) rechallenge in patients with metastatic renal cell carcinoma who progressed on prior ICI: A systematic review and meta-analysis.Org: University of Kentucky, Lexington, KY,
Abstract
Safety and tolerability of immune checkpoint inhibitor (CPI) use in advanced hepatocellular carcinoma (aHCC) with Child-Pugh (CP) class B and C.Org: UC Irvine, University of California Irvine, UCI Health,
Abstract
Evaluating patient adherence and persistence to first-line tyrosine-kinase inhibitors for metastatic renal cell carcinoma.Org: UCI Medical Center, Hoag Family Cancer Institute and University of Southern California, University of California Irvine, Pfizer, Pfizer Inc., London, United Kingdom,
Abstract
Trends in FDA approval of solid tumor therapies with analysis of single-agent vs. combination therapies.Org: Oregon Health and Sciences University, University of California Riverside, Medical Oncology Group, Oregon Health & Science University, Oregon Health & Science University, Department of Medicine, Division of Hematology and Medical Oncology, Knight Cancer Institute,
Abstract
Nivolumab (Nivo) plus ipilimumab (Ipi) 6-month treatment versus continuation in patients with advanced non-small-cell-lung cancer (aNSCLC): 3-year results of the IFCT-1701 DICIPLE phase 3 trial.Org: Université Paris Cité, Thoracic Oncology Department & CIC Inserm 1425, Hôpital Bichat Claude Bernard, AP-HP.Nord, Hôpital Bichat Claude Bernard, AP-HP.Nord, Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy,
Abstract
Real world utilization and outcomes of immunotherapy regimens in metastatic castration resistant prostate cancer (mCRPC).Org: Tisch Cancer Institute, Division of Hematology and Medical Oncology, Mayo Clinic, Scottsdale, AZ, Icahn School of Medicine at Mount Sinai/Tisch Cancer Institute, New York, NY,
Abstract
Utility of circulating tumor DNA as a tool to detect minimal residual disease in patients with metastatic cancer and durable response following treatment with immune checkpoint inhibitors.Org: Norris Cotton Cancer Center Dartmouth-Hitchcock Medical Center, Hanover Medical School, NHS Greater Glasgow and Clyde, Dartmouth College/Giesel School of Medicine, Dartmouth-Hitchcock Medical Center,
Abstract
Imaging response to immune checkpoint inhibitors in patients with advanced melanoma: A retrospective observational cohort study.Org: Arnie Charbonneau Cancer Research Institute, University of Calgary, Department of Medicine, Icahn School of Medicine at Mount Sinai, University of Alberta, Tom Baker Cancer Centre,